compound-348u87 has been researched along with HIV-Infections* in 2 studies
1 review(s) available for compound-348u87 and HIV-Infections
| Article | Year |
|---|---|
Potential for combined therapy with 348U87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir-resistant herpes simplex virus infection.
Inhibitors of the ribonucleotide reductase of herpes simplex viruses (HSV) potentiate the activity of acyclovir in vitro and in animal studies. In addition, the combination of the ribonucleotide reductase inhibitor 348U87 and acyclovir has synergistic therapeutic effects against infections in mice due to thymidine kinase-deficient, thymidine kinase-altered, and DNA polymerase mutants of HSV. We performed a pilot study of topical combination therapy with 348U87 (3%) and acyclovir (5%) cream for acyclovir-resistant, anogenital HSV infections in ten human immunodeficiency virus (HIV)-infected patients. Our results, with lack of complete reepitheliazation of lesions in all patients and poor virologic response, suggest that this therapy is unlikely to be useful for this indication. Topics: Acyclovir; Animals; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Herpes Simplex; HIV Infections; Humans; Hydrazones; Pilot Projects; Pyridines | 1993 |
1 other study(ies) available for compound-348u87 and HIV-Infections
| Article | Year |
|---|---|
Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir.
The thiocarbonohydrazone 348U87 inactivates herpes simplex virus ribonucleotide reductase and potentiates the activity of acyclovir against wild-type and acyclovir-resistant strains of herpes simplex virus. We treated 10 human immunodeficiency virus-infected patients with acyclovir-resistant anogenital herpes simplex virus infection with a topical preparation of 348U87 (3%) in combination with acyclovir (5%) in an open-labelled study. Transient improvement with combination therapy occurred frequently; however, target lesions reepithelialized completely in only 1 of 10 patients. Termination of study drug therapy was most often due to cessation of therapeutic effect before complete resolution of lesions. As currently formulated, topical 348U87 offers little therapeutic benefit for this indication. Topics: Acyclovir; Administration, Topical; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Herpes Genitalis; HIV Infections; Humans; Hydrazones; Male; Pyridines; Ribonucleotide Reductases; Simplexvirus | 1993 |